Jubilant Pharmova Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1140.00 +8.90 (0.79%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1110.1
Today’s High
1155
52 Week Low
408.6
52 Week High
1309
1135.50 +5.00 (0.44%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1117.5
Today’s High
1157.4
52 Week Low
409.4
52 Week High
1309.9
Key Metrics
- Market Cap (In Cr) 17906.75
- Beta 1.89
- Div. Yield (%) 0.44
- P/B 3.29
- TTM P/E 30.76
- Peg Ratio -0.62
- Sector P/E 31.15
- D/E 0.52
- Open Price 1110.1
- Prev Close 1131.1
Jubilant Pharmova Analysis
Price Analysis
-
1 Week-7.78%
-
3 Months26.06%
-
6 Month60.95%
-
YTD107.26%
-
1 Year159.68%
Risk Meter
- 45% Low risk
- 45% Moderate risk
- 45% Balanced Risk
- 45% High risk
- 45% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 2
- 2
- Buy
- 1
- 1
- 1
- 0
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 3
- 3
- 3
- 2
Jubilant Pharmova News
Stocks to Watch: IDFC First Bank, PNB, Dr Reddy's, REC, RIL, Welspun and more
2 min read . 30 Sep 2024India's Warren Buffetts are betting on these five under-the-radar stocks
10 min read . 19 Aug 2024Rakesh Jhunjhunwala Multibagger stocks- Geojit, NCC among the top 4 this year
1 min read . 14 Aug 2024Jubilant Pharmova Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 6702.9
- Selling/ General/ Admin Expenses Total
- 2216
- Depreciation/ Amortization
- 381.9
- Other Operating Expenses Total
- 1445.4
- Total Operating Expense
- 6352.9
- Operating Income
- 350
- Net Income Before Taxes
- 170.5
- Net Income
- 77.1
- Diluted Normalized EPS
- 9.4
- Period
- 2024
- Total Assets
- 11548.5
- Total Liabilities
- 6114.6
- Total Equity
- 5433.9
- Tangible Book Valueper Share Common Eq
- 121.67
- Period
- 2024
- Cashfrom Operating Activities
- 971.3
- Cashfrom Investing Activities
- -607.9
- Cashfrom Financing Activities
- -432.5
- Net Changein Cash
- -57.5
- Period
- 2023
- Total Revenue
- 6281.73
- Selling/ General/ Admin Expenses Total
- 3219.05
- Depreciation/ Amortization
- 382.6
- Other Operating Expenses Total
- 56.03
- Total Operating Expense
- 6108.72
- Operating Income
- 173.01
- Net Income Before Taxes
- 27.78
- Net Income
- -60.98
- Diluted Normalized EPS
- 5.6
- Period
- 2023
- Total Assets
- 11156.65
- Total Liabilities
- 5757.37
- Total Equity
- 5399.28
- Tangible Book Valueper Share Common Eq
- 126.96
- Period
- 2023
- Cashfrom Operating Activities
- 660.67
- Cashfrom Investing Activities
- -544.41
- Cashfrom Financing Activities
- -156.68
- Net Changein Cash
- 30.1
- Period
- 2022
- Total Revenue
- 6130.16
- Selling/ General/ Admin Expenses Total
- 3107.09
- Depreciation/ Amortization
- 381.7
- Other Operating Expenses Total
- 29.93
- Total Operating Expense
- 5305.71
- Operating Income
- 824.45
- Net Income Before Taxes
- 630.45
- Net Income
- 413.94
- Diluted Normalized EPS
- 26.14
- Period
- 2022
- Total Assets
- 9990.87
- Total Liabilities
- 4672.3
- Total Equity
- 5318.56
- Tangible Book Valueper Share Common Eq
- 135.04
- Period
- 2022
- Cashfrom Operating Activities
- 837.54
- Cashfrom Investing Activities
- -380.37
- Cashfrom Financing Activities
- -32.6
- Net Changein Cash
- 481.86
- Period
- 2021
- Total Revenue
- 6098.54
- Selling/ General/ Admin Expenses Total
- 2850.19
- Depreciation/ Amortization
- 426.07
- Other Operating Expenses Total
- -75.43
- Total Operating Expense
- 5001.09
- Operating Income
- 1097.44
- Net Income Before Taxes
- 871.08
- Net Income
- 835.87
- Diluted Normalized EPS
- 38.26
- Period
- 2021
- Total Assets
- 8918.11
- Total Liabilities
- 4176.62
- Total Equity
- 4741.49
- Tangible Book Valueper Share Common Eq
- 113.77
- Period
- 2021
- Cashfrom Operating Activities
- 1707.28
- Cashfrom Investing Activities
- -739.01
- Cashfrom Financing Activities
- -1709.39
- Net Changein Cash
- -728.86
- Period
- 2020
- Total Revenue
- 5975.79
- Selling/ General/ Admin Expenses Total
- 2758.84
- Depreciation/ Amortization
- 431.55
- Other Operating Expenses Total
- -101.59
- Total Operating Expense
- 4800.38
- Operating Income
- 1175.41
- Net Income Before Taxes
- 1012.88
- Net Income
- 898.25
- Diluted Normalized EPS
- 40.43
- Period
- 2020
- Total Assets
- 12521.65
- Total Liabilities
- 6917.77
- Total Equity
- 5603.88
- Tangible Book Valueper Share Common Eq
- 174.72
- Period
- 2020
- Cashfrom Operating Activities
- 1542.94
- Cashfrom Investing Activities
- -327
- Cashfrom Financing Activities
- -1050.37
- Net Changein Cash
- 225.42
- Period
- 2019
- Total Revenue
- 9110.82
- Selling/ General/ Admin Expenses Total
- 3482.21
- Depreciation/ Amortization
- 360.3
- Other Operating Expenses Total
- 54.41
- Total Operating Expense
- 8009
- Operating Income
- 1101.82
- Net Income Before Taxes
- 903.81
- Net Income
- 574.46
- Diluted Normalized EPS
- 48.96
- Period
- 2019
- Total Assets
- 11468.51
- Total Liabilities
- 6659.59
- Total Equity
- 4808.92
- Tangible Book Valueper Share Common Eq
- 134.8
- Period
- 2019
- Cashfrom Operating Activities
- 1121.51
- Cashfrom Investing Activities
- -1011.84
- Cashfrom Financing Activities
- 657.43
- Net Changein Cash
- 761.22
- Period
- 2018
- Total Revenue
- 7557.81
- Selling/ General/ Admin Expenses Total
- 2806.34
- Depreciation/ Amortization
- 324.03
- Other Operating Expenses Total
- 39.23
- Total Operating Expense
- 6450.37
- Operating Income
- 1107.44
- Net Income Before Taxes
- 859.08
- Net Income
- 642.81
- Diluted Normalized EPS
- 45.76
- Period
- 2018
- Total Assets
- 9617.62
- Total Liabilities
- 5531.09
- Total Equity
- 4086.53
- Tangible Book Valueper Share Common Eq
- 94.65
- Period
- 2018
- Cashfrom Operating Activities
- 1303.2
- Cashfrom Investing Activities
- -617.7
- Cashfrom Financing Activities
- -901.14
- Net Changein Cash
- -212.27
- Period
- 2024-09-30
- Total Revenue
- 1752.3
- Selling/ General/ Admin Expenses Total
- 564.3
- Depreciation/ Amortization
- 91.4
- Other Operating Expenses Total
- 343.8
- Total Operating Expense
- 1568.5
- Operating Income
- 183.8
- Net Income Before Taxes
- 144.4
- Net Income
- 102.8
- Diluted Normalized EPS
- 7.09
- Period
- 2024-09-30
- Total Assets
- 11924.4
- Total Liabilities
- 5983.9
- Total Equity
- 5940.5
- Tangible Book Valueper Share Common Eq
- 150.71
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 327.5
- Cashfrom Investing Activities
- 635.8
- Cashfrom Financing Activities
- -848.5
- Net Changein Cash
- 120.5
- Period
- 2024-06-30
- Total Revenue
- 1731.7
- Selling/ General/ Admin Expenses Total
- 552.9
- Depreciation/ Amortization
- 90.7
- Other Operating Expenses Total
- 365.6
- Total Operating Expense
- 1175
- Operating Income
- 556.7
- Net Income Before Taxes
- 499.7
- Net Income
- 482.1
- Diluted Normalized EPS
- 6.34
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1758.6
- Selling/ General/ Admin Expenses Total
- 555
- Depreciation/ Amortization
- 101
- Other Operating Expenses Total
- 404.8
- Total Operating Expense
- 1757.1
- Operating Income
- 1.5
- Net Income Before Taxes
- -53.7
- Net Income
- -58.6
- Diluted Normalized EPS
- 3.22
- Period
- 2024-03-31
- Total Assets
- 11548.5
- Total Liabilities
- 6114.6
- Total Equity
- 5433.9
- Tangible Book Valueper Share Common Eq
- 121.67
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 971.3
- Cashfrom Investing Activities
- -607.9
- Cashfrom Financing Activities
- -432.5
- Net Changein Cash
- -57.5
- Period
- 2023-12-31
- Total Revenue
- 1677.1
- Selling/ General/ Admin Expenses Total
- 581.5
- Depreciation/ Amortization
- 94.6
- Other Operating Expenses Total
- 341.7
- Total Operating Expense
- 1553.7
- Operating Income
- 123.4
- Net Income Before Taxes
- 101
- Net Income
- 66.8
- Diluted Normalized EPS
- 4.2
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1680.3
- Selling/ General/ Admin Expenses Total
- 531.8
- Depreciation/ Amortization
- 96.6
- Other Operating Expenses Total
- 349.4
- Total Operating Expense
- 1535.1
- Operating Income
- 145.2
- Net Income Before Taxes
- 98
- Net Income
- 62.5
- Diluted Normalized EPS
- 3.94
- Period
- 2023-09-30
- Total Assets
- 11399.6
- Total Liabilities
- 5989.5
- Total Equity
- 5410.1
- Tangible Book Valueper Share Common Eq
- 122.82
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 531.2
- Cashfrom Investing Activities
- -341.3
- Cashfrom Financing Activities
- -239.4
- Net Changein Cash
- -40.2
- Period
- 2023-06-30
- Total Revenue
- 1586.9
- Selling/ General/ Admin Expenses Total
- 547.7
- Depreciation/ Amortization
- 89.7
- Other Operating Expenses Total
- 349.5
- Total Operating Expense
- 1507
- Operating Income
- 79.9
- Net Income Before Taxes
- 25.2
- Net Income
- 6.4
- Diluted Normalized EPS
- 0.4
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 1678
- Selling/ General/ Admin Expenses Total
- 534.3
- Depreciation/ Amortization
- 271.23
- Other Operating Expenses Total
- 394.71
- Total Operating Expense
- 1730.01
- Operating Income
- -52.01
- Net Income Before Taxes
- -86.41
- Net Income
- -97.84
- Diluted Normalized EPS
- -6.12
- Period
- 2023-03-31
- Total Assets
- 11156.65
- Total Liabilities
- 5757.37
- Total Equity
- 5399.28
- Tangible Book Valueper Share Common Eq
- 126.96
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 660.67
- Cashfrom Investing Activities
- -544.41
- Cashfrom Financing Activities
- -156.68
- Net Changein Cash
- 30.1
- Period
- 2022-12-31
- Total Revenue
- 1552.51
- Selling/ General/ Admin Expenses Total
- 567.94
- Depreciation/ Amortization
- 94.28
- Other Operating Expenses Total
- 360.62
- Total Operating Expense
- 1500.91
- Operating Income
- 51.6
- Net Income Before Taxes
- 8.73
- Net Income
- -15.67
- Diluted Normalized EPS
- -0.98
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Jubilant Pharmova Technical
Moving Average
SMA
- 5 Day1174.51
- 10 Day1210.66
- 20 Day1176.64
- 50 Day1155.49
- 100 Day979.33
- 300 Day808.14
Jubilant Pharmova Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Wockhardt
- 1158.2
- -28.75
- -2.42
- 1334.55
- 321
- 17836.28
- Eris Lifesciences
- 1370.85
- 6.45
- 0.47
- 1521.05
- 810.1
- 18647.44
- Jubilant Pharmova
- 1140
- 8.9
- 0.79
- 1309
- 408.6
- 18051.98
- Caplin Point Laboratories
- 1941.95
- -9.35
- -0.48
- 2175
- 1179.95
- 14747.51
- Sanofi India
- 6050
- -98.95
- -1.61
- 7593.6
- 4382.64
- 13933.53
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Wockhardt
- -
- 5.41
- -10.63
- -12.7
- Eris Lifesciences
- 47.3
- 7.2
- 20.71
- 24.96
- Jubilant Pharmova
- 120.43
- 3.29
- 6.15
- 5.13
- Caplin Point Laboratories
- 32.55
- 6.4
- 22.81
- 25.39
- Sanofi India
- 23.92
- 13.95
- 31.61
- 21.03
Jubilant Pharmova Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 25-Oct-24
- Quarterly Results
- 19-Jul-24
- Quarterly Results
- 29-May-24
- Audited Results & Final Dividend
- 02-Feb-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 19-Jul-23
- Quarterly Results
- 29-May-23
- Audited Results & Final Dividend
- 03-Feb-23
- Quarterly Results
- 21-Oct-22
- Quarterly Results
- 02-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Aug-24
- 12-Aug-24
- AGM
- 25-Aug-24
- 30-Jul-24
- POM
- 28-Jun-24
- 28-May-24
- POM
- 27-Jan-24
- 28-Dec-23
- POM
- 31-Aug-23
- 29-May-23
- AGM
- 23-Aug-23
- 24-Jul-23
- POM
- 14-Apr-23
- 14-Mar-23
- POM
- 26-Sept-22
- 01-Jul-22
- AGM
- 18-May-22
- 18-Apr-22
- POM
- 22-Sept-21
- 04-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-May-24
- 02-Aug-24
- 02-Aug-24
- 5
- 29-May-23
- 10-Aug-23
- 10-Aug-23
- 5
- 04-Jun-21
- 06-Aug-21
- 05-Aug-21
- 5